NICE posted a detailed report from the
As stated on NICE's website, the reason for selecting Multikine is the following: 'Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of
A detailed Health Technology Briefing prepared by the NIHR posted on NICE's website titled 'Leukocyte interleukin with cyclophosphamide, indomethacin, and zinc for neoadjuvant therapy of squamous cell carcinoma of the head and neck' can viewed in full HERE .
The NICE briefing includes the following statements: 'The current standard of care for locally advanced SCCHN is an aggressive combined modality therapy. With current treatment the risk of recurrence, distant metastases, and death (5-year survival rate) for patients remains high.'
'With current standard of care, most patients with SCCHN still experience disease recurrence or develop distant metastases (spread to distant organs or lymph nodes), therefore novel treatment options are needed.'
'The LI injection [Multikine] utilizes naturally occurring, immune-regulating cytokines, and could be the first investigational immunotherapeutic to be used in locally advanced SCCHN. Results from phase III clinical trial ( NCT01265849 ) indicated a statistically significant 5-year survival benefit with LI immunotherapy produced in patients receiving surgery plus radiotherapy, representing approximately 40% of the study population.'
'If licensed, LI [Multikine] will offer the first-line neoadjuvant treatment in previously untreated patients with SCCHN prior to standard of care.'
Dr.
'We are highly encouraged that NICE has selected Multikine for evaluation as a potential new standard of care for head and neck cancer. This is a big step forward in the
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words 'intends,' 'believes,' 'anticipated,' 'plans' and 'expects,' and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in
Multikine (Leukocyte Interleukin, Injection) is the trademark that
Contact:
Tel: (703) 506-9460
Tel: +1 (703) 506-9460
Email: feedback@cel-sci.com
(C) 2023 Electronic News Publishing, source